APPEAL Antivirus Pandemic Preparedness EuropeAn pLatform
- Coordinator
- Universitatsklinikum Jena, Germany
- Runs
- 1 January 2024 to 31 December 2028
- Status
- Running
- EU funding
- €7.6m
- Total cost
- €7.6m
- Partners
- 15 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101137311
What the project is doing
In the project's own words, from its summary on CORDIS.
Developing new antiviral treatment against viruses and particularly high-priority emerging and re-emerging viruses as listed by the WHO, remains crucial as, among other aspects, the viruses evolve under selection. Broad spectrum host-directed antiviral drugs (HDA) are promising therapeutic options, however the robust identification of relevant host factors by genome-wide knockout screens is challenging due to low consistency in the resulting hits.
Our project aims to (1) establish a computational and experimental pipeline to identify and validate an antiviral for these viruses, and (2) identify at least one broad spectrum antiviral drug against potential emerging and re-emerging viruses as listed by the WHO. To address these, we will implement a drug selection pipeline following several strategies: We will employ (i) machine learning, based on data from knockout screens, proteomics, protein interaction, transcriptomics of infected cells with pandemic-related viruses, Genome-Wide Association Studies, and generic gene descriptors, (ii) High Density Cell Arrays, which provide much more detailed readouts compared to state of the art pooled knockout screens, (iii) primary cell cultures obtained from a diverse array of human tissues, as they are more appropriate to study the host cell physiology during infection, compared to cancer cell lines, and (iv) use the pipeline to identify host restriction factors, which, when activated, challenge the virus; followed by innovative drug development and delivery based on small activating RNA.
The pipeline comprises an Expedited Arm for which broad spectrum antiviral drugs for repurposing will be selected followed by in vitro and in vivo efficacy testing, and a clinical trial as a proof of concept. The elaborated Arm includes all strategies (i)-(iv) and will provide a sustainable pandemic preparedness pipeline ready-to-operate to identify the appropriate treatment against the emerging virus at the early time of a new outbreak.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitatsklinikum Jena | Jena | Germany | Coordinator |
| European Research Infrastructure on Highly Pathogenic Agents | Bruxelles / Brussel | Belgium | Participant |
| Consultech Technologieberatung GmbH | Berlin | Germany | Participant |
| Johann Wolfgang Goethe-Universitaet Frankfurt Am Main | Frankfurt Am Main | Germany | Participant |
| Pharmai Discovery GmbH | Dresden | Germany | Participant |
| Ruprecht-Karls-Universitaet Heidelberg | Heidelberg | Germany | Participant |
| Technische Universitaet Muenchen | Muenchen | Germany | Participant |
| Universitatsmedizin Greifswald Korperschaft Des Offentlichen Rechts | Greifswald | Germany | Participant |
| Acondicionamiento Tarrasense Associacion | Terrassa | Spain | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Participant |
| Ecrin European Clinical Research Infrastructure Network | Paris | France | Participant |
| Institut Pasteur | Paris | France | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Third party |
| Mattek in Vitro Life Science Laboratories Sro | Bratislava | Slovakia | Participant |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI